Business Context and Reporting Period
Company: DarioHealth Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2017
Reporting Period: Single event date (July 20, 2017)
Business Context: The registrant is an emerging growth company based in Israel focused on mobile health applications.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is a regulatory milestone rather than a financial variance:
- Regulatory Clearance: The U.S. Food and Drug Administration (FDA) granted Pre-market Notification (510(k)) clearance for the Dario app.
- Device Compatibility: Clearance applies to specific Android smart mobile devices, including the Samsung Galaxy S series, Samsung Galaxy Note series, and LG G series.
- Market Access: This clearance enables the launch of the Dario app in the United States Google Play store.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful receipt of FDA clearance, facilitating U.S. market entry for the specified Android devices.
Guidance and Outlook: The filing text does not provide specific financial guidance or forward-looking projections.
Risks and Contingencies: No specific risks or contingencies are detailed in this specific 8-K filing beyond the implicit operational requirement to launch the app following clearance.
Key Facts for Investor Verification
- Verify the specific scope of the FDA 510(k) clearance to ensure it covers all intended device models and functionalities.
- Confirm the actual launch date of the Dario app on the U.S. Google Play store following this clearance.
- Review subsequent filings for financial impact analysis regarding the U.S. market expansion.